VIATRIS VTRSV 深 沪
等待开盘 04-02 09:30:00 美东时间
15.66
0.000
0.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 15.66
- 总市值 0
- 52周最高 16.13
- 市盈率 静 30.42
- 换手率 NaN.00%
- 52周最低 15.33
- 委 比 0.00%
- 总股本 0
- 历史最高 15.97
- 量 比 0
- 振 幅 0.00%
- 历史最低 15.33
- 每 手 1
- 风险率 0.00%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多BRIEF-FDA Accepts Viatris Supplemental New Drug Application For Mr-141 (Phentolamine Ophthalmic Solution 0.75%) For The Treatment Of Presbyopia
BRIEF-FDA Accepts Viatris Supplemental New Drug Application For Mr-141 (Phentolamine Ophthalmic Solution 0.75%) For The Treatment Of Presbyopia Feb 25 (Reuters) - Viatris Inc VTRS.O : FDA ACCEPTS VIATRIS SUPPLEMENTAL NEW DRUG APPLICATION FOR MR-141 (PHENTOLAMINE OPHTHALMIC SOLUTION 0.75%) FOR THE TR
02-25 20:00
BRIEF-Viatris Provides Pipeline Update On Four Regulatory Milestones
Dec 18 (Reuters) - Viatris Inc VTRS.O: VIATRIS PROVIDES PIPELINE UPDATE ON FOUR REGULATORY MILESTONES Source text: ID:nPn4f0sGza Further company coverage: VTRS.O ((Reuters.Briefs@thomsonreuters.com;))
2025-12-18 20:03
BRIEF-Viatris Q3 Adjusted EPS USD 0.67 Vs. IBES Estimate USD 0.62
Nov 06 (Reuters) - Viatris Q3 revenue USD 3,759.9 million vs. IBES estimate USD 3,608 million. Q3 EPS USD -0.11 VIATRIS Q3 NET INCOME USD -128.2 MILLION VIATRIS OUTLOOK FY REVENUE USD 13,900-14,300 MI...
2025-11-06 19:59
BRIEF-Viatris Announces Appointment Of David Simmons To The Company's Board Of Directors
Viatris Inc VTRS.O: VIATRIS ANNOUNCES APPOINTMENT OF DAVID SIMMONS TO THE COMPANY'S BOARD OF DIRECTORS Source text: ID:nPn2tDb46a Further company coverage: VTRS.O
2025-08-05 19:55
BRIEF-Viatris Provides Update On Phase 3 Study Of Mr-139 For Blepharitis
Viatris Inc VTRS.O: VIATRIS PROVIDES UPDATE ON PHASE 3 STUDY OF MR-139 FOR BLEPHARITIS VIATRIS INC - PHASE 3 STUDY OF MR-139 DID NOT MEET PRIMARY ENDPOINT VIATRIS INC - EVALUATING NEXT STEPS FOR PHASE...
2025-07-18 20:27
BRIEF-Viatris Announces Positive Top-Line Results From Second Pivotal Phase 3 Vega-3 Trial
June 26 (Reuters) - Viatris Inc VTRS.O: VIATRIS ANNOUNCES POSITIVE TOP-LINE RESULTS FROM SECOND PIVOTAL PHASE 3 VEGA-3 TRIAL OF MR-141 IN PRESBYOPIA VIATRIS INC - MR-141 MEETS PRIMARY AND SECONDARY EN...
2025-06-26 18:58
BRIEF-EMA's CHMP Re-Examines Rejection Of Kisunla For Early Alzheimer’S Treatment
June 20 (Reuters) - EMA's CHMP: POSITIVE OPINION WAS ADOPTED FOR OGSIVEO, FOR THE TREATMENT OF ADULTS WITH PROGRESSING DESMOID TUMOURS NINTEDANIB VIATRIS GOT POSITIVE OPINION FOR TREATMENT OF IDIOPATH...
2025-06-20 18:17
Viatris Inc. (VTRS) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
LOS ANGELES, June 2, 2025 /PRNewswire/ -- Glancy Prongay & Murray LLP announces that investors with losses have opportunity to lead the securities fraud class action lawsuit against Viatris ...
2025-06-03 00:00
BRIEF-Viatris Announces Positive Top-Line Results From Phase 3 Lynx-2 Trial Of Mr-142 In Keratorefractive Patients With Visual Disturbances Under Mesopic, Low-Contrast Conditions
June 2 (Reuters) - Viatris Inc VTRS.O: VIATRIS ANNOUNCES POSITIVE TOP-LINE RESULTS FROM PHASE 3 LYNX-2 TRIAL OF MR-142 IN KERATOREFRACTIVE PATIENTS WITH VISUAL DISTURBANCES UNDER MESOPIC, LOW-CONTRAST...
2025-06-02 20:19
BRIEF-Viatris Announces Positive Results From Phase 3 Study Of Investigational Xulane Lo™ Low Dose Patch For Birth Control In Women Of Childbearing Potential
May 8 (Reuters) - Viatris Inc VTRS.O: VIATRIS ANNOUNCES POSITIVE RESULTS FROM PHASE 3 STUDY OF INVESTIGATIONAL XULANE LO™ LOW DOSE PATCH FOR BIRTH CONTROL IN WOMEN OF CHILDBEARING POTENTIAL VIATRIS IN...
2025-05-08 18:54
